Kaposiform Hemangioendothelioma: a Retrospective Study of 33 Steroid-Resistant Cases Treated with Vincristine and Long Follow-Ups

Wang Zuopeng,Li Kai,Yao Wei,Dong Kuiran,Xiao Xianmin,Zheng Shan
DOI: https://doi.org/10.3760/cma.j.issn.0253-3006.2015.07.008
2015-01-01
Abstract:Objective To evaluate the efficacy of vincristine (VCR) in the treatment of steroidresistant patients of kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP).Methods Retrospective analyses were conducted for the clinical data of 33 steroid-resistant cases of KHE with KMP on VCR at our hospital from March 2003 to March 2013.Results There were 19 boys and 14 girls.Their age during an initial diagnosis of KHE was 1 day to 10 months.Seven lesions were located in superficial soft tissue while deep soft tissue was involved in 26 cases.All cases were diagnosed with thrombocytopenia and 25 had coagulopathy.None of them was responsive to steroids before starting VCR treatment.And 22 cases achieved complete remission with a normalization of platelet count within (7.5 ± 5.2) weeks after VCR treatment.The masses shrank in size or became rofter at an average of (4.9 ± 2.6) weeks.Two cases had a partial response and 1 case stayed in treatment.And 8 cases had no obvious response to VCR and switched to other treatments.For 24 withdrawal cases,the average course of treatment was (31.1 ± 6.0) weeks.The mean and longest follow-up periods was 3.7 and 7.1 years respectively.And there was no recurrence.Conclusions VCR is both safe and effective in the treatment of steroid-resistant cases of KHE with KMP.And it should be app1ied early and recommended as a first line option.
What problem does this paper attempt to address?